About Transplant Genomics
Transplant Genomics is a Healthcare company based in Los Angeles (United States) founded in 2013, and was acquired by Eurofins Scientific in June 2019. Molecular diagnostic tests for early graft injury detection are developed. It operates on a HealthTech model. Transplant Genomics has raised $20.6 million across 7 funding rounds from investors including Eurofins Scientific. Its chief executive, as recorded, is Stanley Rose. Transplant Genomics offers products and services including TruGraf Kidney, OmniGraf Liver, and Eurofins TRAC Kidney dd-cfDNA. Its focus areas include Biotechnology and Molecular Diagnostics. Its legal entity is Eurofins Transplant Genomics. Its competitors include Foundation Medicine, Personalis and Veritas Genetics; 3 of its 3 listed competitors have raised funding.
Company details
Molecular diagnostic tests are provided by Eurofins Transplant Genomics to improve organ transplant outcomes. Early signs of graft injury are detected, actionable causes are differentiated, and therapy optimization is enabled. Focus is placed on kidney and liver transplantation with tests like TruGraf Kidney and OmniGraf Liver. The healthcare sector, specifically biotechnology and molecular diagnostics, is served through genetic biomarker-guided solutions.
- Headquarters Los Angeles, United States
- Stage Acquired
- SectorsHealthcare
- Phone•••• ••••
- Website transplantgenomics.com
- Social LinkedIn
- Acquired by Eurofins Scientific (Jun 2019)
- Legal Name Eurofins Transplant Genomics
- Total Equity Funding$20.6M (USD)
in 7 rounds
- Latest Funding Round$7.98M (USD), Series A
Aug 2018
- Investors
- Acquired byEurofins Scientific
(Jun 2019)
Products & Services of Transplant Genomics
Transplant Genomics offers a comprehensive portfolio of products and services, including TruGraf Kidney, OmniGraf Liver, and Eurofins TRAC Kidney dd-cfDNA.
Surveillance for subclinical acute rejection in kidneys is provided.
Immunosuppression optimization for liver transplant patients is offered.
Clinical acute rejection detection in kidneys is facilitated.
Funding Insights of Transplant Genomics
Transplant Genomics has successfully raised a total of $20.6M across 7 strategic funding rounds. The most recent funding activity was a Series A round of $7.98 million completed in August 2018. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $20.6M
- Total Rounds 7
- Last Round Series A — $7.98M
- First Round $2.82M
(Apr 2014)
All 7 funding rounds of Transplant Genomics with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Aug 2018 | $7.98M | Series A | – | – | – |
| Apr 2017 | $3.17M | Series A | – | – | – |
| Feb 2017 | $1.71M | Series A | – | – | – |
| May 2016 | $530,000 | Series A | – | – | – |
| Oct 2015 | $1.2M | Series A | – | – | – |
| May 2015 | $3.2M | Series A | – | – | – |
| Apr 2014 | $2.82M | Series A | – | – | – |
1 investors in total: 1 institutional.
Investors in Transplant Genomics
Transplant Genomics has secured backing from 1 investor. Prominent investors backing the company include Eurofins Scientific.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Laboratory testing and contract research services are provided globally. | 1987 | eurofins.com | Luxembourg, Luxembourg |
Investor details for Transplant Genomics
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
People of Transplant Genomics
23 people are tracked at Transplant Genomics (4 in leadership, 10 in board & advisors, 9 in team).
| Name | Role | Group |
|---|---|---|
Stanley Rose | CEO & President | Leadership |
Chris Schlotzhauer | National Sales Director | Leadership |
John Holman | Vp, Medical Affairs | Leadership |
Alexander Vatz | Vice President Of Transplant Diagnostic Sales | Leadership |
Bruce Kaplan | Board Member | Board & advisors |
Vinaya Rao | Board Member | Board & advisors |
Fuad Shihab | Board Member | Board & advisors |
David Axelrod | Board Member | Board & advisors |
Matthew Cooper | Board Member | Board & advisors |
Jonathan Bromberg | Board Member | Board & advisors |
Anil Chandraker | Board Member | Board & advisors |
Emilio Poggio | Board Member | Board & advisors |
Gabriel Danovitch | Board Member | Board & advisors |
Robert Fairchild | Board Member | Board & advisors |
Angel Arroyo | Regional Transplant Manager | Team |
Timarla Johnson | Manager Of Client Services | Team |
Stephanie Clifford | Field Service Liaison Manager - Eastern U.s. | Team |
Jay Phillips | Regional Transplant Manager | Team |
Juan Carlos T. | Client Support Manager | Team |
Cory Reynolds Sales Leader Organ Transplant Medical Device | Regional Transplant Manager | Team |
3 more people are available in the full profile.
Complete people profiles for Transplant Genomics
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
Timeline of Transplant Genomics
4 dated milestones of Transplant Genomics across 6 years, from founding to its latest funding, stage changes and deals.
- Founded Transplant Genomics is founded.
- Funding First funding round of $2.8M.
- Funding Latest funding round, Series A, of $8.0M.
- Exit Acquired by Eurofins Scientific.
Competitors of Transplant Genomics
Transplant Genomics has 3 listed competitors in our database, 3 of them funded. They include Foundation Medicine, Personalis and Veritas Genetics.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| foundationmedicine.com | 2010 | Cambridge, United States | $96.5M | 1,707 | Genomics-based diagnostic tests for cancer are provided. | |
| personalis.com | 2011 | Menlo Park, United States | $87.3M | 310 | Genomic sequencing and diagnosis software is provided for healthcare. | |
| veritasgenetics.com | 2014 | Danvers, United States | $53.38M | 14 | Genetic testing products for health risks and traits are offered. |
Detailed competitors of Transplant Genomics
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Web traffic of Transplant Genomics
The website of Transplant Genomics (transplantgenomics.com) receives about 2.1K visits a month.
- Monthly visits2.1K
▼ 0.6% vs previous month
Top companies in Genomics & Gene Therapy Platforms
3 companies that operate in the same segment as Transplant Genomics (Genomics & Gene Therapy Platforms) in United States, ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
mRNA-based therapeutics for diseases including cancer and infections are developed. | 2010 | Cambridge, Massachusetts, United States | USD 2.78 B | USD 1.94 B | 5,800 | |
Digital sequencing technology for cancer detection is developed. | 2012 | Redwood City, California, United States | USD 557.5 M | USD 982.02 M | 4,867 | |
Circulating tumor DNA is screened for early cancer detection. | 2016 | Menlo Park, California, United States | USD 2 B | USD 147.17 M | 1,141 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Transplant Genomics
Complete news archive for Transplant Genomics
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Transplant Genomics
Transplant Genomics was founded in 2013 and raised its 1st funding round 1 year after it was founded.
Transplant Genomics is headquartered in Los Angeles, United States. It is registered at Los Angeles, California, United States.
Stanley Rose is the CEO of Transplant Genomics, as recorded in our data.
Transplant Genomics is a funded company, having raised a total of $20.6M across 7 funding rounds to date. The company's 1st funding round was a Series A of $2.82M, raised on Apr 2014.
Molecular diagnostic tests are provided by Eurofins Transplant Genomics to improve organ transplant outcomes. Early signs of graft injury are detected, actionable causes are differentiated, and therapy optimization is enabled. Focus is placed on kidney and liver transplantation with tests like TruGraf Kidney and OmniGraf Liver. The healthcare sector, specifically biotechnology and molecular diagnostics, is served through genetic biomarker-guided solutions.
Transplant Genomics's top competitors include Foundation Medicine, Personalis and Veritas Genetics.
Transplant Genomics offers TruGraf Kidney, OmniGraf Liver, and Eurofins TRAC Kidney dd-cfDNA.
Transplant Genomics has 1 investor. Key investors include Eurofins Scientific.
Transplant Genomics operates through Eurofins Transplant Genomics.
Yes. Transplant Genomics was acquired by Eurofins Scientific in June 2019.